Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
  • Alerts
  • Podcasts
  • Subscriptions

Predicting outcomes and drug resistance with new standardised treatment

P.R. Mohapatra, D.T. Hari
European Respiratory Journal 2011 37: 974; DOI: 10.1183/09031936.00161010
P.R. Mohapatra
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: prmohapatra@hotmail.com
D.T. Hari
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editors:

In their hypothetical cohorts Oxlade et al. 1 predicted significant public-health benefits by changing from the 8-month to the 6-month (2HRZE/6HE to 2HRZE/4HR; where H = isoniazid, R = rifampicin, Z = pyrazinamide and E = ethambutol) regimen. Data from 2008 on drug-resistance surveillance from five World Health Organization (WHO) regions, i.e. Africa (Botswanaa), Western Pacific (China), Africa (Mozambiquea), South-East Asia (Burma) and Europe (Tajikistan), has shown isoniazid resistances among newly diagnosed cases varies from 9.0% to 26.6% and among previously treated cases from 11.7% to 74.4% 2. India and China carry the greatest estimated burden of multidrug-resistant (MDR)-tuberculosis (TB), together accounting for almost 50% of the total cases worldwide 2 The incidence of mono-drug resistance among new cases in tuberculosis endemic countries is also high 3. Relapse cases (from all previously mentioned sites) had 5.5 times higher odds of harbouring MDR-TB strains when compared with new cases (95% CI 4.4–6.8), after adjusting for the clustering effect at the country level 2.

The WHO has recommended discontinuation of the regimen that doesn’t have rifampicin in the continuation phase (to replace HE by HR) 2. Thus, rifampicin should be part of regimen throughout the treatment period; both in the intensive and continuation phase. Again the use of isoniazid and rifampicin in the continuation phase of the 6-month regimen (2HRZE/4HR) could lead to acquired MDR in the areas where the incidence of mono-drug resistance among new cases is high 4. By using HR in the case of mono-resistance to isoniazid, practically only rifampicin is given during continuation phase. Therefore, the third recommendation of the WHO guidelines states: “In populations with known or suspected high levels of isoniazid resistance, new TB patients may receive HRE as therapy in the continuation phase as an acceptable alternative to HR” 4. Thus, in areas with higher levels of isoniazid resistance, newly diagnosed TB patients should receive 2HRZE/4HRE instead of 2HRZE/4HR (three-drug regimen in continuation phase) instead of HR or HE. Therefore, it will be more effective if the authors in their hypothetical cohorts could predict and compare the benefits of the 6-month regimen containing HRE in the continuation phase of the proposed regimen, i.e. 2HRZE/4HRE, and predict the outcomes of the new proposed regimen.

Worldwide intermittent regimens are widely administered. The authors only predicted the benefits of daily regimens but remained silent about the intermittent therapy in their hypothetical cohorts.

Footnotes

  • Statement of Interest

    None declared.

  • ©2011 ERS

REFERENCES

  1. ↵
    1. Oxlade O,
    2. Schwartzman K,
    3. Pai M,
    4. et al
    . Predicting outcomes and drug resistance with standardised treatment of active tuberculosis. Eur Respir J 2010; 36: 870–877.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva, World Health Organization, 2010. Available from www.who.int/tb/features_archive/world_tb_day_2010/en/index.html.
  3. ↵
    Individual country profiles. Anti tuberculosis drug resistance in the world. http://whqlibdoc.who.int/hq/2000/WHO_CDS_TB_2000.278_Annex2.pdf.
  4. ↵
    World Health Organization. Treatment of Tuberculosis Guidelines. 4th Edition. Geneva, World Health Organization, 2009.
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 37 Issue 4 Table of Contents
European Respiratory Journal: 37 (4)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Predicting outcomes and drug resistance with new standardised treatment
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Predicting outcomes and drug resistance with new standardised treatment
P.R. Mohapatra, D.T. Hari
European Respiratory Journal Apr 2011, 37 (4) 974; DOI: 10.1183/09031936.00161010

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Predicting outcomes and drug resistance with new standardised treatment
P.R. Mohapatra, D.T. Hari
European Respiratory Journal Apr 2011, 37 (4) 974; DOI: 10.1183/09031936.00161010
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Testing bronchodilator responsiveness
  • Testing bronchodilator responsiveness
  • Pharmacodynamics and pharmacokinetics in nontuberculosis mycobacteria infections
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Collections
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2019 by the European Respiratory Society